Patent application title:

Bioadhesive gel based on hydroxyethycellulose

Publication number:

US20070031479A1

Publication date:
Application number:

10/567,890

Filed date:

2004-07-30

Abstract:

Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent.

Inventors:

Interested in similar patents?

Get notified when new applications in this technology area are published.

Classification:

A61K9/0036 »  CPC main

Medicinal preparations characterised by special physical form; Galenical forms characterised by the site of application; Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms

A61K47/10 »  CPC further

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient; Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

A61K47/38 »  CPC further

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient; Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates; Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin Cellulose; Derivatives thereof

A61P15/00 »  CPC further

Drugs for genital or sexual disorders ; Contraceptives

A61P31/00 »  CPC further

Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/04 »  CPC further

Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics Antibacterial agents

A61P31/10 »  CPC further

Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics Antimycotics

A61P37/08 »  CPC further

Drugs for immunological or allergic disorders Antiallergic agents

A61K9/70 IPC

Medicinal preparations characterised by special physical form Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

A61K31/7034 IPC

Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof; Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

A61K31/4196 IPC

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole 1,2,4-Triazoles

A61K31/4178 IPC

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole 1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

A61K31/192 IPC

Medicinal preparations containing organic active ingredients; Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids; Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid

Description

This invention relates to compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles.

Bioadhesion is the property whereby some hydrogels adhere to biological tissues, in particular to mucous-coated epithelia such as the gastric, buccal, vaginal and rectal mucosae.

This property has been exploited to develop drug delivery systems, especially in order to increase the time over which drugs remain in contact with certain sites or areas of therapeutic interest, giving rise to systemic effects (thus increasing transmucosal absorption) or local effects.

The most commonly used polymers that are capable of forming hydrogels and imparting bio- and/or muco-adhesion are acrylic or methacrylic acid polymers, possibly cross-linked, and chitosan, or its derivatives.

In particular, for drugs designed for gynaecological use, a bioadhesive gel able to ensure prolonged contact between the active ingredient and the vaginal mucosa, and gradual release of that ingredient over time, provides the ideal solution in terms of efficacy and compliance by patients.

Bioadhesive vaginal gels have consequently been disclosed, for example, in U.S. Pat. No. 6,159,491, US 2002012674, US 2003091642, WO 200047144, WO 200203896, WO 200143720 and WO 9610989. In all these cases, an acrylic acid polymer (Carbomer or polycarbophil) is used as viscosity-controlling or bioadhesive agent.

WO 200015192 describes mucoadhesive formulations in which chitosan is used instead of the acrylic acid polymer.

However, the problem of obtaining a bioadhesive formulation that presents the following advantages and properties:

    • release of drug for up to approximately 24 hours;
    • absence of gelling/bioadhesive agents, characterised by the presence of acid groups, which are therefore sensitive to the ionic strength of the medium, and sometimes need to be neutralised with bases;
    • the possibility of carrying drugs with different chemico-physical properties, in particular water-soluble drugs and lipophilic drugs which are substantially insoluble in water;
    • reduction of the time and cost of the treatment remains substantially unsolved.

It has now been found that said objectives can be achieved by bioadhesive gel formulations that adhere to the mucous membranes, in particular the vaginal mucosa, comprising hydroxyethylcellulose as the only bioadhesive polymer. This gelling excipient has no acid groups and is therefore not dependent on the ionic strength of the medium; it also has a matrix effect which allows particularly slow, gradual release of the active ingredient, for up to 24 hours.

This invention therefore relates to compositions in the form of an aqueous gel for the intravaginal delivery of active ingredients, comprising hydroxyethylcellulose as the only gelling and bioadhesive agent.

The compositions of the invention may also contain glycerol, diethylene glycol monoethyl ether, surfactants, preservatives, acidifiers and other excipients in common use for the form of delivery considered herein.

The compositions of the invention will preferably contain 1 to 5% by weight of hydroxyethylcellulose, 25 to 90% by weight of water, 5 to 25% by weight of glycerol, 5 to 50% by weight of diethylene glycol monoethyl ether, 0.01 to 10% by weight of surfactants, 0.05 to 1% by weight of preservatives, and 0.01 to 1% by weight of acidifiers.

Preferably, the hydroxyethylcellulose content is higher than 2% and less than 4%.

Hydroxyethylcellulose is commercially available from many sources: it is preferred an hydroxyethylcellulose having a degree of substitution of about 1.5 (corresponding to 3 hydroxyethyl groups every two saccharide units) and a molecular weight estimated from intrinsic viscosity measurements ranging from 1.0 to 1.3×106. Hydroxyethylcellulose having said characteristic is available under the trade-mark Natrosol 250 HX by Hercules Inc. UK.

The percentage of active ingredient will obviously depend on the characteristics of the selected drug, and may vary within a wide range, for example from 0.01 to 10% by weight.

Active ingredients which can be advantageously formulated according to the invention include antifungals, antiseptics and antimicrobials, antibiotics, analgesics, local anaesthetics, antihistamines, anti-inflammatory agents, contraceptives, hormones, and combinations thereof.

Examples of these active ingredients include, in particular, econazole, miconazole, fluconazole, ciclopiroxolamine, nifuratel, nystatin, chlorhexidine, ibuprofen, ketoprofen, naproxen, benzydamine, benzalkonium chloride or other quaternary ammonium antiseptics, nonoxynol-9 and all other active ingredients of interest for gynaecological applications.

The following examples illustrate the invention in greater detail.

EXAMPLE 1

Composition Percentage
Purified water 81.9%
Glycerol 12.9%
Chlorhexidine digluconate, 20% solution w/v 2.7%
Hydroxyethylcellulose (Natrosol 250 HX) 2.5%

EXAMPLE 2 Ibuprofen Vaginal Gel

Composition Percentage
Ibuprofen 0.100%
Benzalkonium chloride 0.150%
Polyoxyethyen-20-monocetyl ether (Brij 58) 0.500%
Hydroxyethylcellulose (Natrosol 250 HX) 2.500%
Diethylene glycol monoethyl ester (Transcutol P) 10.000%
Purified water 86.750%

EXAMPLE 3 Econazole Nitrate Vaginal Gel

Composition Percentage
Econazole nitrate 1.000%
Benzalkonium chloride 0.150%
Hydroxyethylcellulose (Natrosol 250 HX) 2.500%
Polysorbate 80 (Tween 80) 4.000%
Glycerol 10.000%
Diethylene glycol monoethyl ester (Transcutol P) 40.000%
Purified water 42.350%

EXAMPLE 4 Study Of Bioadhesion Of Vaginal Gels

Bioadhesion was measured in vitro using a suitably modified Lloyd dynamometer. The measurement substrate (rabbit gastric mucosa or polypropylene) was fixed with an adhesive to the upper support, which in turn was connected to the mobile crossbar, and 200 mg of the test formulation were placed on the lower support so as to cover the surface evenly. After effecting close contact between the formulation and the substrate (30 s), the crossbar was raised at a defined, constant speed until the two surfaces separated.

A 20 N load cell was used for the measurements [J. Y. Chang, Y-K. Oh, H. S. Kong, E. J. Kim et al., J. Control. Release 82 (2002) 39-50; S. Skulason, T. Kristmundsdottir, W. P. Holbrook, Bio-Gels Pharmaceuticals].

Five measurements were taken for each sample; the parameters considered were the maximum breaking load (ML) and the adhesion work (W).

The operating conditions used in the study are reported below.

Apparatus Lloyd LRX Tensiometer
Equipped with clamps for adhesion tests
Test conditions Crossbar speed 0.1 mm/s
Load cell 20 N
Contact time between substrate and gel 30 s
Contact surface rabbit gastric mucosa/
polypropylene

Results

The results are shown in Table 1.

TABLE 1
Rabbit
gastric mucosa Polypropylene
FORMULATION ML (N) W (Nmm) ML (N) W (Nmm)
EXAMPLE 1 0.088 ± 0.017 0.095 ± 0.030 0.101 ± 0.019 0.099 ± 0.014
EXAMPLE 2 0.076 ± 0.012 0.069 ± 0.010
EXAMPLE 3 0.179 ± 0.032 0.155 ± 0.032

EXAMPLE 5 pH 4.0 Diffusion Test of Gels of Examples 1, 2 and 3

Diffusion medium: lactate buffer, pH 4.0

Diffusion volume: 50 mL

Temperature: 37±0.5° C.

Agitation speed: 50 rpm

Quantity of sample: 1.5 g

Release area: 4.5 cm2

Release membrane: cellulose acetate 0.45 μm.

The test for release of the drug from the gel was performed using diffusion cells, with cellulose acetate membranes having a 4.5 cm2 surface. The quantity of gel applied was 1.5 g. At given times, an automated system took predetermined sample aliquots, with immediate UV spectrophotometer at 254 nm.

FIG. 1 shows the diffusion profile of chlorhexidine as the mean of 8±standard deviation.

FIG. 2 shows the diffusion profile of chlorhexidine from the 8 samples.

Table 2 shows the percentages released for the 8 chlorhexidine samples.

TABLE 2
time sample 1 sample 2 sample 3 sample 4 sample 5 sample 6 sample 7 sample 8 mean SD
0 0 0 0 0 0 0 0 0 0 0
10 12.89 8.532 11.94 10.37 11.54 4.473 12.28 9.514 10.19 2.74
20 20.05 19.09 19.92 19.39 18.9 17.3 20.35 18.51 19.19 0.98
30 25.29 23.73 26.29 24.53 23.49 22.86 25.73 24.65 24.57 1.17
40 29.94 28.16 31.35 29.54 27.11 27.24 29.5 27.47 28.79 1.53
60 37.63 33.33 39.02 38.09 34.48 35.99 37.73 35.43 36.46 1.97
90 48.43 45.46 51.11 50.36 42.11 40.69 45.84 43.93 45.99 3.76
120 57.25 53.77 59.81 60.04 49.54 51.69 53.37 51.09 54.57 4.01
150 64.1 60.13 65.16 64.99 56.34 60.75 62.1 60.35 61.74 2.99
180 69.83 65.88 70.99 72.06 59.42 64.05 65.88 63.19 66.41 4.31
210 75.2 72.57 76.17 79.41 66.23 70.77 71.62 69.9 72.73 4.10
240 78.71 74.61 79.33 82.52 69.9 73.52 74.98 73.03 75.83 4.07
270 81.79 78.38 81.54 84.88 72.61 77.04 77.86 74.84 78.62 3.99
300 84.36 81.24 83.65 87.96 76.38 79.6 80.6 79.33 81.64 3.58

FIG. 3 shows the diffusion profile of ibuprofen as the mean of 8 samples±standard deviation.

Table 3 shows the percentages released for the 8 ibuprofen samples.

TABLE 3
time
(min) sample 1 sample 2 sample 3 sample 4 sample 5 sample 6 sample 7 sample 8 mean SD
0 0 0 0 0 0 0 0 0 0 0
30 15.56 17.83 18.96 18.96 4.18 3.22 17.06 11.26 13.38 6.05
60 24.34 26.60 26.88 19.53 33.15 24.14 26.71 19.95 25.16 4.06
90 30.56 28.02 32.26 28.02 34.44 36.37 30.57 37.01 32.16 3.28
120 40.19 33.39 45.28 30.56 36.05 44.74 42.16 39.59 38.99 4.94
150 47.26 47.54 45.56 56.60 47.63 44.74 43.77 43.77 47.11 3.89
180 57.45 41.60 53.49 46.69 47.31 44.74 44.09 44.41 47.47 4.99
240 57.73 54.62 54.62 59.71 52.11 51.81 53.03 52.11 54.47 2.70
300 68.20 61.69 59.99 63.67 68.88 61.87 69.49 62.17 64.49 3.52
360 70.18 66.79 64.24 59.71 76.80 74.67 69.79 71.31 69.19 5.17
420 61.98 74.99 65.65 73.30 77.41 84.72 77.71 76.50 74.03 6.73
480 78.39 72.16 71.60 71.31 81.98 84.72 81.07 80.15 77.67 4.93

FIG. 4 shows the diffusion profile of econazole as the mean of 8 samples±standard deviation.

Table 4 shows the percentages released of the 8 econazole samples.

TABLE 4
time sample 1 sample 2 sample 3 sample 4 sample 5 sample 6 sample 7 sample 8 mean SD
1 8.9 8.9 10.7 11.7 9.1 8.8 10.3 12 10.1 1.3
2 12.3 15.5 18.4 19.1 14.4 15 17.3 19.5 16.4 2.5
3 24.1 21.6 24 25 22.1 25.3 21.1 23.6 23.4 1.6
4 29 26.2 28.8 30.1 30.4 28.2 25.8 32.1 28.8 2.1
5 34.1 30.4 32.8 34.5 36 33.4 30.2 33.7 33.1 2.0
6 40 34.2 35.4 37.6 38.4 36.5 34 36.3 36.6 2.1
7 40.5 36.8 37.4 39.9 41 39.2 37 38.4 38.8 1.6
8 44.4 39.3 38.6 41.3 43.2 40.2 39.6 41.2 41.0 2.0
9 45.2 40.6 40 43 45.8 42.1 42.3 44.2 42.9 2.1
10 46.1 41.8 40.9 44 47.3 44 45 45.4 44.3 2.1
11 47.2 42.8 41.4 44.8 48 45.3 46.3 46.7 45.3 2.3
12 48.6 43.6 42.6 45.8 49.2 47.1 48.2 48.1 46.7 2.4
13 49.2 44.3 43.1 46.4 50.3 49.6 50.2 49.2 47.8 2.8
14 50.2 45.2 43.6 46.9 51 49.8 50.8 50.1 48.5 2.8
15 50.7 45.4 43.7 47.6 51.1 50 51.1 50.6 48.8 2.9
16 51.3 46 44.3 47.4 51.3 50.3 51.4 50.8 49.1 2.8
17 51.9 46.3 44.7 47.7 51.5 50.4 51.7 50.9 49.4 2.8
18 52.6 46.3 45 47.7 51.7 50.7 51.9 51.1 49.6 2.9
19 53.1 46.8 46.7 48.2 52 51.1 52 51.3 50.2 2.5
20 53.3 46.9 49.3 50.1 52.2 51.2 52.3 51.5 50.9 2.0
21 53.1 47 52.2 50.3 52.3 51.4 52.6 51.7 51.3 1.9
22 53.9 47.8 54.2 51.2 52.5 51.6 52.7 51.9 52.0 2.0
23 54.1 48.3 55.3 51.9 52.7 51.8 52.9 52.2 52.4 2.0
24 55.2 50.1 56.1 52 53.2 52.4 53.1 52.4 53.1 1.9

Claims

1. A composition in the form of an aqueous bioadhesive gel adapted for the delivery of at least one of active ingredients and principles, said composition comprising hydroxyethylcellulose as the only gelling agent and a bioadhesive agent, glycerol and diethylene glycol monoethyl ether, together with at least one surfactant, preservative and acidifier.

2. The composition as claimed in claim 1, comprising 1 to 5% by weight of hydroxyethylcellulose, 25 to 90% by weight of water, 5 to 25% by weight of glycerol, 5 to 50% by weight of diethylene glycol monoethyl ether, 0.01 to 10% by weight of surfactant, 0.05 to 1% by weight of preservative, and 0.01 to 1% weight of acidifier.

3. The composition as claimed in claim 1 further comprising, as an active constituent, at least one selected from the group consisting of antifungals, antiseptics, antimicrobials, antibiotics, analgesics, local anaesthetics, antihistamines, anti-inflammatory agents, contraceptives, hormones, and combinations thereof.

4. The composition as claimed in claim 3, wherein the active constituent is at least one selected from the group consisting of econazole, miconazole, fluconazole, cyclopiroxolamine, nifuratel, nystatin, chlorhexidine, ibuprofen, ketoprofen, naproxen, benzydamine, benzalkonium chloride or other quaternary ammonium antiseptics, and nonxynol-9.

5-6. (canceled)

Resources

Images & Drawings included:

Sources:

Recent applications in this class: